BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

PLoS By Category | Recent PLoS Articles
Gastroenterology and Hepatology - Immunology - Infectious Diseases - Public Health and Epidemiology - Surgery

Liver Retransplantation in Adults: The Largest Multicenter Italian Study
Published: Friday, October 05, 2012
Author: Umberto Maggi et al.

by Umberto Maggi, Enzo Andorno, Giorgio Rossi, Luciano De Carlis, Umberto Cillo, Fabrizio Bresadola, Vincenzo Mazzaferro, Andrea Risaliti, Paolo Bertoli, Dario Consonni, Francesco Barretta, Tullia De Feo, Mario Scalamogna

This study is the largest Italian survey on liver retransplantations (RET). Data report on 167 adult patients who received 2 grafts, 16 who received 3 grafts, and one who received 4 grafts over a 11 yr period. There was no statistically significant difference in graft survival after the first or the second RET (52, 40, and 29% vs 44, 36, and 18% at 1,5,and 10 yr, respectively: Log-Rank test, p?=?0.30). Survivals at 1, 5, and 10 years of patients who underwent 2 (n?=?151) or 3 (n?=?15) RETs, were 65, 48,and 39% vs 59, 44, and 30%, respectively (p?=?0.59). Multivariate analysis of survival showed that only the type of graft (whole vs reduced) was associated with a statistically significant difference (HR?=?3.77, Wald test p?=?0. 05); the donor age appeared to be a relevant factor as well, although the difference was not statistically significant (HR?=?1.91, Wald test p?=?0.08). Though late RETs have better results on long term survival relative to early RETs, no statistically significant difference can be found in early results, till three years after RET. Considering late first RETs (interval>30 days from previous transplantation) with whole grafts the difference in graft survival in RETs due to HCV recurrence (n?=?17) was not significantly different from RETs due to other causes (n?=?53) (65–58 and 31% vs 66–57 and 28% respectively at 1–5 and 10 years, p?=?0.66).